Survival analysis of oropharyngeal squamous cell carcinoma patients linked to histopathology, disease stage, tumor stage, risk factors, and received therapy
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-1.14147Keywords:
oropharyngeal squamous cell carcinoma, risk factors, survival ratesAbstract
Summary. Background: Survival of oropharyngeal squamous cell carcinoma (OSCC) patients depends on the risk and environmental factors, tumor biology, achievements in diagnostics and treatment approaches. Aim: To perform a survival analysis of the patients with OSCC treated over a 10-year period in a single hospital in Latvia linking these data to histopathological findings, risk factors and received therapy. Materials and Methods: The main outcome measures were overall and disease-specific survival (OS and DS) along with histopathology analysis. Results: Kaplan – Meier survival analysis showed better survival for females, younger patients lacking bad habits, operated and received radiotherapy, with lower T grade and disease stage. Cox regression showed diminished early death risk in patients with lower T grade, no regional metastases (N0) and bad habits, operated and received radiotherapy. A vast majority of tumors were localized in palatine tonsils and the base of the tongue. The localization did not correlate with mean survival time/survival. Lower OS (p = 0.03) and DS (p = 0.026) were estimated for patients with pharyngeal wall and tonsillar involvement compared to tumors localized in the soft palate. A histological variant of tumor seemed irrelevant estimating OS and DS, whereas therapeutic modalities significantly affected survival. Conclusions: OSCC patients with lower T grade, N0 status, lacking bad habits, and surgically treated had better survival.
References
De Camargo Cancela M, de Souza DL, Curado MP. International incidence of oropharyngeal cancer: a population-based study. Oral Oncol 2012; 48: 484–90.
Fossum CC, Chintakuntlawar AV, Price DL, et al. Characterization of the oropharynx: anatomy, histology, immunology, squamous cell carcinoma and surgical resection. Histopathology 2017; 70: 1021–9.
Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 2007; 29: 779–92.
Gourin C, Johnson JT. Surgical treatment of squamous cell carcinoma of the base of tongue. Head Neck 2001; 23: 653–60.
Osborne RF, Brown JJ. Carcinoma of the oral pharynx: an analysis of subsite treatment heterogeneity. Surg Oncol Clin N Am 2004; 13: 71–80.
Cohan DM, Popat S, Kaplan SE, et al. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg 2009; 17: 88–94.
Pires FR, Ramos AB, de Oliveira JBC, et al. Oral squamous cell carcinoma: clinicopathological features from 346 cases from a single Oral Pathology service during an 8-year period. J Appl Oral Sci 2013; 21: 460–7.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63: 11–30.
Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294–301.
Bychkov VA, Nikitina EG, Ibragimova MK, et al. Comprehensive meta-analytical summary on human papillomavirus association with head and neck cancer. Exp Oncol 2016; 38: 68–72.
Szybiak B, Trzeciak P, Golusiński W. Role of extended histological examination in the assessment of local recurrence of tongue and floor of the mouth cancer. Rep Pract Oncol Radiother 2012; 17: 319–23.
Amit M, Yen TC, Liao CT, et al. Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study. Cancer 2013; 119: 4242–8.
Shimizu S, Miyazaki A, Sonoda T, et al. Tumor budding is an independent prognostic marker in early stage oral squamous cell carcinoma: With special reference to the mode of invasion and worst pattern of invasion. PLoS One 2018; 13: e0195451.
Garzino-Demo P, Zavattero E, Franco P, et al. Parameters and outcomes in 525 patients operated on for oral squamous cell carcinoma. J Craniomaxillofac Surg 2016; 44: 1414–21.
López-Cedrún JL, Andrés de Llano J. A 22 years survival and prognostic factors analysis in a homogeneous series of 64 patients with advanced cancer of the tongue and the floor of the mouth. J Craniomaxillofac Surg 2015; 43: 376–81.
Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005; 29: 167–78.
Uma D, Raja RS, Simion C. Margin assessment in oral squamous cell carcinoma. Cancer 2013; 120: 452–3.
Benhamou CA, Laraqui N, Touhami M, et al. Tobacco and cancer of the larynx: a prospective survey of 58 patients. Rev Laryngol Otol Rhinol (Bord) 1992; 113: 285–8.
Winkelstein W. Smoking and cervical cancer—current status: a review. Am J Epidemiol 1990; 131: 945–57.
Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumor type. J Intern Med 2002; 252: 206–24.
Farsi NJ, Rousseau MC, Schlecht N, et al. Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. Carcinogenesis 2017; 38: 1188–95.
Pitchers M, Martin C. Delay in referral of oropharyngeal squamous cell carcinoma to secondary care correlates with a more advanced stage at presentation, and is associated with poorer survival. Br J Cancer 2006; 94: 955–8.
Yuan Y, Wang L, Li Q-X, et al. Retrospective study of survival in human papillomavirus-negative oropharyngeal squamous cell carcinoma treated with primary surgery and associated prognostic factors. Onco Targets Ther 2018; 11: 2355–62.
Zelefsky MJ, Harrison LB, Armstrong JG. Long-term treatment results of postoperative radiation therapy for advanced stage oropharyngeal carcinoma. Cancer 1992; 70: 2388–95.
Ling W, Mijiti A, and Moming A. Survival pattern and prognostic factors of patients with squamous cell carcinoma of the tongue: a retrospective analysis of 210 cases. Oral Maxillofac Surg 2013; 71: 775–85.
Karatzanis AD, Psychogios G, Mantsopoulos G, et al. Management of advanced carcinoma of the base of tongue. J Surg Onc 2012; 106: 713–8.
Rades D, Seibold ND, Gebhard MP, et al. Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 2011; 187: 626–32.
Kamran SC, Qureshi MM, Jalisi S, et al. Primary surgery versus primary radiation-based treatment for locally advanced oropharyngeal cancer. Laryngoscope 2018; 128: 1353–64.
Münscher A, Bussmann L, Sehner S, et al. Survival analysis of 287 oropharyngeal squamous cell carcinoma patients in a single institution: a retrospective comparison of two consecutive time intervals with surgical and conservative treatment approaches. Eur Arch Otorhinolaryngol 2017; 274: 3211–9.
Lanzer M, Zemann W, Lübbers T, et al. Do patients with oral and oropharyngeal squamous cell carcinoma benefit from elective contralateral neck dissection? A long-term analysis. Head Neck Oncol 2012; 4: 70.
Donaduzzi LC, De-Conto F, Kuze LS, et al. Occurrence of contralateral lymph neck node metastasis in patients with squamous cell carcinoma of the oral cavity. J Clin Exp Dent 2014; 6: 209–13.
Cho KJ, Joo YH, Sun DI, et al. Management of cervical lymph node metastasis in tonsillar squamous cell carcinoma: It is necessary to treat node-negative contralateral neck? Auris Nasus Larynx 2011; 38: 501–7.
Al-Mamgani A, van Werkhoven E, Navran A, et al. Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: A literature-based critical review. Cancer Treat Rev 2017; 59: 102–8.
Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019; 393: 40–50.
Dovšak T, Ihan A, Didanovič V, et al. Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer. BMC Cancer 2018; 18: 235.
Psychogios G, Mantsopoulos K, Bohr C, et al. Incidence of occult cervical metastasis in head and neck carcinomas: development over time. J Surg Oncol 2013; 107: 384–7.
Fasunla AJ, Greene BH, Timmesfeld N, et al. A meta-analysis of the randomized controlled trials on elective neck dissection versus therapeutic neck dissection in oral cavity cancers with clinically node-negative neck. Oral Oncol 2011; 47: 320–4.
Kau RJ, Alexiou C, Stimmer H, et al. Diagnostic procedures for detection of lymph node metastases in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec 2000; 62: 199–203.
Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709–20.
Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626–36.
Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125–31.
Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21: 1510–7.
Andrews E, Seaman WT, Webster-Cyriaque J. Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV. Oral Oncol 2009; 45: 486–91.
Ernster JA, Sciotto CG, O’Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007; 117: 2115–28.
Capote-Moreno A, Naval L, Muñoz-Guerra MF, et al. Prognostic factors influencing contralateral neck lymph node metastases in oral and oropharyngeal carcinoma. J Oral Maxillofac Surg 2010; 68: 268–75.
Süslü N, Hoşal AS, Aslan T, et al. Carcinoma of the oral tongue: a case series analysis of prognostic factors and surgical outcomes. J Oral Maxillofac Surg 2013; 71: 1283–90.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
